BioCentury | Apr 29, 2020
Distillery Therapeutics

Inhibiting endocytosis to enhance cetuximab, trastuzumab and Bavencio antitumor efficacy

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer; skin cancer Blocking endocytosis with DMN inhibitors could enhance the efficacy of cetuximab, trastuzumab and Bavencio avelumab against skin, breast and colorectal cancers. The mAbs target EGFR,...
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

DBV expects delay for peanut allergy product  DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said the Aug. 5 PDUFA date for its peanut allergy therapy may be extended as FDA has raised questions on the long-term efficacy...
BC Extra | Jan 14, 2020
Clinical News

Complete response to NK cell therapy prompts NantKwest to plan pivotal trials

NantKwest is planning registration trials for its off-the-shelf NK cell therapy in triple-negative breast cancer and pancreatic cancer after compassionate use of PD-L1.t-haNK led to a complete response in one patient. The data, reported at...
BC Extra | Jan 7, 2020
Company News

Jan. 6 Company Quick Takes: China approvals for AZ, Sanofi and Gene+; plus Apollomics-GlycoMimetics, Pfizer-Merck KGaA and more

Trio of approvals from China’s NMPA   China’s National Medical Products Administration approved NDAs for Lokelma sodium zirconium cyclosilicate from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat hyperkalemia and anti-PCSK9 mAb Praluent alirocumab from Sanofi (Euronext:SAN;...
BC Extra | Oct 30, 2019
Company News

Oct. 29 Company Quick Takes: Incyte’s JAK inhibitor beats expectations; plus Sumitomo-Intercept, Merck KGaA-Pfizer, AMAG, Regeneron-Sanofi

Incyte surges on Jakafi sales, guidance  On the strength of 3Q19 sales of Jakafi ruxolitinib that beat estimates and resulted in an increase in full-year guidance, Incyte Corp. (NASDAQ:INCY) climbed $3.49 to $83.35 Tuesday, adding...
BC Extra | Sep 20, 2019
Company News

Xospata poised for EU approval under accelerated assessment

EMA's CHMP recommended approval of Xospata for acute myelogenous leukemia in its September roundup. Under accelerated assessment, the agency backed Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) as monotherapy for relapsed or refractory AML in...
BC Innovations | Sep 12, 2019
Distillery Therapeutics

Inhibition of G9A and DNMT methyltransferases in bladder cancer

DISEASE CATEGORY: Cancer INDICATION: Bladder cancer Dual inhibition of G9A and DNMT methyltransferases, in combination with cisplatin and anti-programmed cell death 1 ligand 1 (PD-L1), could help to treat bladder cancer. A tool compound that...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

A tumor-targeted Bavencio conjugate with enhanced antitumor efficacy

DISEASE CATEGORY: Cancer INDICATION: Melanoma Coupling a pegylated α-MSH analog to anti-PD-1 antibodies could enhance antitumor immunity. α-MSH is the ligand for MC1R, a receptor upregulated in melanoma cells. Conjugating the α-MSH analog to the...
BioCentury | Jul 13, 2019
Tools & Techniques

Broadening role for external control arms in clinical trials

External control arms are moving from theory to practice as drug developers begin to use them to make internal go/no-go decisions for clinical programs and to support regulatory applications. The field is largely split between...
BC Innovations | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
Items per page:
1 - 10 of 120